Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Posts Earnings Results, Beats Estimates By $0.33 EPS

Posted by Paula Ricardo on Nov 12th, 2026

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.33, FiscalAI reports. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. The business had revenue of $3.17 million during the quarter, compared to the consensus estimate of $0.45 million.

Armata Pharmaceuticals Stock Down 4.4%

Shares of Armata Pharmaceuticals stock traded down $0.17 on Thursday, hitting $3.72. The company’s stock had a trading volume of 105,066 shares, compared to its average volume of 119,290. Armata Pharmaceuticals has a 52-week low of $2.74 and a 52-week high of $14.98. The firm has a fifty day moving average price of $3.87 and a 200-day moving average price of $6.87. The company has a market capitalization of $138.31 million, a P/E ratio of -0.49 and a beta of 1.54.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Armata Pharmaceuticals in a report on Tuesday, September 22nd. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Armata Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $15.00.

Get Our Latest Research Report on ARMP

Armata Pharmaceuticals Company Profile

(Get Free Report)

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics. The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus .